FIELD: immunology and virology.
SUBSTANCE: invention concerns immune-biological agent (versions) and method of its use (versions). Immune-biological agent can be obtained based on human adenovirus serotype 5 containing cassette with insertion of modified gene GP of virus Ebola /H.sapiens-wt/SLE/2014/Makona-EM124.1 GenBank ID KM233045.1 with sequence selected from SEQ ID NO 1, SEQ ID NO 2 (version 1). Also the immune-biological agent can be obtained on basis of vesicular stomatitis virus, containing a cassette with insertion of modified gene GP Ebola virus /H.sapiens-wt/SLE/2014/Makona-EM124.1 GenBank ID KM233045.1 with sequence selected from SEQ ID NO 1, SEQ ID NO 2 (version 2). Besides, immune-biological agent can be obtained based on two vesicular stomatitis virus, one of which contains a cartridge with insertion of unmodified gene GP Ebola virus /H.sapiens-wt/1976/Mayinga/Zaire GenBank ID AF086833.2 with sequence SEQ ID NO 3, and other contains cartridge with insertion of modified gene GP Ebola virus /H.sapiens-wt/SLE/2014/Makona-EM124.1 GenBank ID KM233045.1 with sequence selected from SEQ ID NO 1 , SEQ ID NO 2, wherein said structure are taken in effective ratios (version 3). Methods of using described immune-biological agents for inducing specific immunity to Ebola are realised by introducing into body in an effective amount once or series structures based on different vectors of every 1 week. Presented inventions more effectively induce immune response against Ebola virus in comparison with similar facilities due to introduction of structures based on two different vectors, which enables to obtain more powerful induction of immune response than immunisation same vector.
EFFECT: described solutions can be used as specific preventive agent for diseases caused by Ebola virus.
8 cl, 12 dwg, 5 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST EBOLA VIRUS | 2015 |
|
RU2578159C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCTION OF IMMUNE RESPONSE TO FILOVIRUSES: EBOLAVIRUS AND/OR MARBURGVIRUS, METHOD OF USING IMMUNOBIOLOGICAL AGENT | 2021 |
|
RU2760439C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST LASSA VIRUS AND METHOD FOR USING IT | 2024 |
|
RU2823965C1 |
| IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) | 2018 |
|
RU2709659C1 |
| STRAINS OF HYBRID CELLS OF ANIMALS MUS_ MUSCULUS - PRODUCERS OF MONOCLONAL ANTIBODIES TO PROTEIN GP OF EBOLA VIRUS (SUBTYPE ZAIRE) AND MONOCLONAL ANTIBODIES TO PROTEIN GP OF EBOLA VIRUS (SUBTYPE ZAIRE) | 2017 |
|
RU2686630C1 |
| Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
| ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT PLASMID DNA pEV.CTL AND EV.Th, PROVIDING EXPRESSION OF ARTIFICIAL GENES, AND ARTIFICIAL T-CELL POLYEPITOPE PROTEINS-IMMUNOGENS EV.CTL AND EV.Th CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE | 2018 |
|
RU2713723C1 |
| SINGLE-DOMAIN ANTIBODIES TO EBOLA VIRUS GP PROTEIN FOR IMMUNOTHERAPY OF EBOLA FEVER | 2015 |
|
RU2644202C2 |
| ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733832C1 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2630304C2 |
